NervGen Pharma Corp., a clinical-stage biotech company focused on developing innovative solutions for nervous system damage, has announced that its President & CEO, Mr. Mike Kelly, will be presenting at the Canaccord Genuity 44th Annual Growth Conference. The conference will take place on August 13, 2024, at the InterContinental Boston Hotel in Boston, MA.
During the conference, Mr. Kelly will discuss NervGen’s current and future plans, expectations, and intentions, as well as the company’s ongoing clinical trial for its lead drug candidate, NVG-291, in spinal cord injury. NervGen is dedicated to enabling nervous system repair in the settings of traumatic injury and disease.
In addition to the presentation, members of NervGen’s management team will be available for one-on-one investor meetings at the conference. This provides an opportunity for investors and stakeholders to learn more about the company’s innovative treatments and its commitment to developing solutions for nervous system damage.
NervGen’s lead drug candidate, NVG-291, is currently being evaluated in a Phase 1b/2a clinical trial for spinal cord injury. The company has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS), and spinal cord injury.
For more information about NervGen and its groundbreaking work in nervous system repair, visit the company’s website at www.nervgen.com. Stay updated with the latest news from NervGen by following the company on X, LinkedIn, and Facebook.
Disclaimer: This article contains forward-looking statements, and readers are advised to exercise caution. Actual results may differ materially from those expressed or implied by the forward-looking statements due to various factors, including but not limited to the impact of pandemics, funding availability, and regulatory approvals.